文献速递膀胱癌与上尿路尿路上皮癌

成纤维细胞生长因子受体改变在接受与未接受卡介苗免疫治疗的高级别非肌层浸润性膀胱癌中的预后与预测价值

Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
PubMed 文献 · Eur Urol · 2022-03-26

该回顾性研究纳入263例高级别非肌层浸润性膀胱癌患者,中位随访63个月,43%存在成纤维细胞生长因子受体改变(FGFRa),其中39%为突变、5.7%为融合。无论是否接受卡介苗治疗或整体人群中,FGFRa与无进展生存、无复发生存和疾病特异性生存均无显著差异。

要点

  • FGFRa在高级别NMIBC中常见,占43%(突变39%、融合5.7%)。
  • FGFRa与较低的原位癌伴发率相关。
  • 无论BCG治疗与否或整体人群,FGFRa与PFS、RFS、DSS均无显著差异。

核心结论

  • 在高危NMIBC患者中,FGFRa频繁出现;FGFRa患者常在BCG治疗后出现复发/再发,存在高度未满足的临床需求。

研究设计与样本

  • 德国膀胱癌药物靶点研究倡议联盟评估的汇总数据集,纳入1992年至2015年匹配的临床与基因组数据的pT1 NMIBC患者,为回顾性研究,共263例高级别NMIBC患者,中位随访63个月。

主要发现

  • 32%的患者出现复发,15%进展为肌层浸润性膀胱癌。
  • FGFRa见于43%的患者,包括39%突变和5.7%融合。
  • FGFRa与较低的原位癌伴发率相关。
  • 在BCG治疗或未治疗的患者以及整体人群中,伴有或不伴有FGFRa的患者在PFS、RFS和DSS上均无显著差异。

局限性

  • 局限性包括回顾性设计以及单中心设置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data are available on the prognostic and predictive value of fibroblast growth factor receptor alterations (FGFRa) relative to clinical outcomes in patients with non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To determine whether FGFRa may be clinically useful in stratifying for treatment response in a real-world cohort of patients with pT1 NMIBC treated and untreated with bacillus Calmette-Guérin (BCG) instillation therapy. DESIGN, SETTING, AND PARTICIPANTS: A pooled dataset of matched clinical and genomic data (1992-2015) for pT1 NMIBC patients was assessed by the Bladder Cancer Research Initiative for Drug Targets in Germany consortium. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Key efficacy outcomes were recurrence-free survival (RFS), progression-free survival (PFS), and disease-specific survival (DSS), which were estimated by Kaplan-Meier analysis, with hazard ratios calculated using a multivariate Cox proportional-hazard model. RESULTS AND LIMITATIONS: In this retrospective study of 263 patients with high-grade NMIBC, at a median follow-up of 63 mo, 32% showed recurrence and 15% progressed to muscle-invasive bladder cancer. FGFRa were found in 43% of patients, including 39% mutations and 5.7% fusions. FGFRa were associated with lower rates of concomitant carcinoma in situ. Among patients with or without FGFRa, there was no significant difference in PFS, RFS, and DSS in those who were BCG treated or BCG naive, or in the overall population. Limitations include the retrospective design from a single-center setting. CONCLUSIONS: In patients with high-risk NMIBC, FGFRa were frequently observed. Patients with FGFRa who often exhibit recurrence/relapse after BCG treatment have a high unmet need. PATIENT SUMMARY: Our retrospective study suggests that fibroblast growth factor receptor alterations (FGFRa) occur frequently in non-muscle-invasive bladder cancer (NMIBC). Outcomes were similar with or without FGFRa in patients with NMIBC, both overall and for standard bacillus Calmette-Guérin (BCG) treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mayr R, Eckstein M, Wirtz RM, et al. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. Eur Urol. 2022. PMID: 35351346. doi:10.1016/j.eururo.2022.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。